Related references
Note: Only part of the references are listed.Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
John A. DeSisto et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Santiago Barrio et al.
LEUKEMIA (2019)
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon et al.
BLOOD (2019)
An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma
Shili Xu et al.
CANCER RESEARCH (2019)
Ufbp1 promotes plasma cell development and ER expansion by modulating distinct branches of UPR
Huabin Zhu et al.
NATURE COMMUNICATIONS (2019)
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Jens Hillengass et al.
LANCET ONCOLOGY (2019)
Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies
Alessandro Allegra et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation
Katarzyna Parzych et al.
ONCOGENE (2019)
The Unfolded Protein Response: Detecting and Responding to Fluctuations in the Protein-Folding Capacity of the Endoplasmic Reticulum
G. Elif Karagoz et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2019)
Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment
Adele Chimento et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis
Lenka Besse et al.
HAEMATOLOGICA (2019)
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
A. Besse et al.
LEUKEMIA (2018)
Deubiquitylating enzymes and drug discovery: emerging opportunities
Jeanine A. Harrigan et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Mechanistic insights into ER-associated protein degradation
Xudong Wu et al.
CURRENT OPINION IN CELL BIOLOGY (2018)
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S. Siegel et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties
Sandra Loaiza et al.
BIOMATERIALS (2018)
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma
Christoph Driessen et al.
BLOOD (2018)
The immunoproteasome and thymoproteasome: functions, evolution and human disease
Shigeo Murata et al.
NATURE IMMUNOLOGY (2018)
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
Akito Nakamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma
V Desantis et al.
TRANSLATIONAL ONCOLOGY (2018)
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Dominik Abt et al.
BJU INTERNATIONAL (2018)
Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies
Wilson I. Gonsalves et al.
JCI INSIGHT (2018)
PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma
S. Panchabhai et al.
LEUKEMIA (2017)
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Tingyu Wu et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Development of GLUT4-selective antagonists for multiple myeloma therapy
Changyong Wei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Zdenek Skrott et al.
NATURE (2017)
Modulating the therapeutic response of tumours to dietary serine and glycine starvation
Oliver D. K. Maddocks et al.
NATURE (2017)
The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy
Yong Tae Kwon et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
Ravyn M. Thompson et al.
ONCOTARGET (2017)
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
T. Avril et al.
ONCOGENESIS (2017)
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Herve Avet-Loiseau et al.
BLOOD (2017)
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi et al.
CANCER AND METASTASIS REVIEWS (2017)
Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Esther A. Zaal et al.
CANCER & METABOLISM (2017)
Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin
Jayasree S. Nair et al.
CLINICAL CANCER RESEARCH (2017)
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma
Leo Rasche et al.
BLOOD (2017)
Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine
Ji Zhang et al.
EMBO JOURNAL (2017)
The UPR reduces glucose metabolism via IRE1 signaling
Judith M. van der Harg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients
M. A. Frassanito et al.
LEUKEMIA (2016)
Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells
E. E. Fink et al.
LEUKEMIA (2016)
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
R. Bajpai et al.
ONCOGENE (2016)
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target
Marina Bolzoni et al.
BLOOD (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation
Rajesh Ravindran et al.
NATURE (2016)
Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response
Julie Tellier et al.
NATURE IMMUNOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
In vivo aspects of protein folding and quality control
David Balchin et al.
SCIENCE (2016)
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkBa and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G. Turner et al.
ONCOTARGET (2016)
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming
Irene Riz et al.
ONCOTARGET (2016)
Targeting p97 to Disrupt Protein Homeostasis in Cancer
Pratikkumar Harsukhbhai Vekaria et al.
FRONTIERS IN ONCOLOGY (2016)
The Biology of Proteostasis in Aging and Disease
Johnathan Labbadia et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 84 (2015)
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells
Enrico Milan et al.
AUTOPHAGY (2015)
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Patricia Maiso et al.
CANCER RESEARCH (2015)
GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2
Jiangbin Ye et al.
GENES & DEVELOPMENT (2015)
Surviving protein quality control catastrophes - from cells to organisms
Kim Schneider et al.
JOURNAL OF CELL SCIENCE (2015)
Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib
S. Jagannathan et al.
LEUKEMIA (2015)
Plasma fatty acid profile in multiple myeloma patients
Artur Jurczyszyn et al.
LEUKEMIA RESEARCH (2015)
Nutrient-sensing mechanisms and pathways
Alejo Efeyan et al.
NATURE (2015)
Proteostasis control by the unfolded protein response
Claudio Hetz et al.
NATURE CELL BIOLOGY (2015)
Proteostasis and aging
Susmita Kaushik et al.
NATURE MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma
Jordan Wengrod et al.
SCIENCE SIGNALING (2015)
Dysregulated metabolism contributes to oncogenesis
Matthew D. Hirschey et al.
SEMINARS IN CANCER BIOLOGY (2015)
Type 2 diabetes as a protein misfolding disease
Abhisek Mukherjee et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97
K. Parzych et al.
CELL DEATH & DISEASE (2015)
Phosphorylation of eIF2α triggered by mTORC1 inhibition and PP6C activation is required for autophagy and is aberrant in PP6C-mutated melanoma
Jordan Wengrod et al.
SCIENCE SIGNALING (2015)
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study
Su-Hsin Chang et al.
LANCET HAEMATOLOGY (2015)
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure
David S. Pitcher et al.
EBIOMEDICINE (2015)
Recent advances and future directions in targeting the secretory apparatus in multiple myeloma
Holger W. Auner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir et al.
CLINICAL CANCER RESEARCH (2015)
An Overview of Autophagy: Morphology, Mechanism, and Regulation
Katherine R. Parzych et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Combined autophagy and proteasome inhibition A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma
Dan T. Vogl et al.
AUTOPHAGY (2014)
Enhanced rate of degradation of basic proteins by 26S immunoproteasomes
Mary Raule et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Keeping the eIF2 alpha kinase Gcn2 in check
Beatriz A. Castilho et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma
J. Kummetha Venkata et al.
BLOOD (2014)
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Raymond J. Deshaies
BMC BIOLOGY (2014)
Endoplasmic Reticulum Stress in Malignancy
Hanna J. Clarke et al.
CANCER CELL (2014)
Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97
Zhe Sha et al.
CURRENT BIOLOGY (2014)
Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases
Claudio Hetz et al.
NATURE REVIEWS NEUROSCIENCE (2014)
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab
Gerald S. Falchook et al.
ONCOTARGET (2014)
p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition
Senthil K. Radhakrishnan et al.
ELIFE (2014)
The role of autophagy in plasma cell ontogenesis
Niccolo Pengo et al.
AUTOPHAGY (2013)
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
Aristeidis Chaidos et al.
BLOOD (2013)
Targeting the ubiquitin proteasome system in haematological malignancies
Lisa J. Crawford et al.
BLOOD REVIEWS (2013)
PDK1 inhibition is a novel therapeutic target in multiple myeloma
S. Fujiwara et al.
BRITISH JOURNAL OF CANCER (2013)
Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
W. Y. Sanchez et al.
BRITISH JOURNAL OF CANCER (2013)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo
Aluvia M. Escalante et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
Leonor Puchades-Carrasco et al.
CLINICAL CANCER RESEARCH (2013)
Iron increases the susceptibility of multiple myeloma cells to bortezomib
Alessandro Campanella et al.
HAEMATOLOGICA (2013)
p58IPK-Mediated Attenuation of the Proapoptotic PERK-CHOP Pathway Allows Malignant Progression upon Low Glucose
Anne-Laure Huber et al.
MOLECULAR CELL (2013)
The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression
Wafa B'chir et al.
NUCLEIC ACIDS RESEARCH (2013)
Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells
Holger W. Auner et al.
PLOS ONE (2013)
Amino Acid Deprivation Promotes Tumor Angiogenesis through the GCN2/ATF4 Pathway
Yugang Wang et al.
NEOPLASIA (2013)
Structural Basis of the Unfolded Protein Response
Alexei Korennykh et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 28 (2012)
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition
Jinsong Hu et al.
BLOOD (2012)
Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy
Samuel K. McBrayer et al.
BLOOD (2012)
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
Naoya Mimura et al.
BLOOD (2012)
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
Silvia C. W. Ling et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
High Rate of Antibody Secretion Is not Integral to Plasma Cell Differentiation as Revealed by XBP-1 Deficiency
Nadine Taubenheim et al.
JOURNAL OF IMMUNOLOGY (2012)
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors
Simone Cenci et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition
Amila Suraweera et al.
MOLECULAR CELL (2012)
Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system
Hemmo Meyer et al.
NATURE CELL BIOLOGY (2012)
Mice completely lacking immunoproteasomes show major changes in antigen presentation
Eleanor Z. Kincaid et al.
NATURE IMMUNOLOGY (2012)
Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation
Jose Manuel Tirado-Velez et al.
PLOS ONE (2012)
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing
M. Ri et al.
BLOOD CANCER JOURNAL (2012)
ER stress modulates cellular metabolism
Xiaoli Wang et al.
BIOCHEMICAL JOURNAL (2011)
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma
Ioanna Papandreou et al.
BLOOD (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Proteostenosis and plasma cell pathophysiology
Simone Cenci et al.
CURRENT OPINION IN CELL BIOLOGY (2011)
Metabolomics of B to Plasma Cell Differentiation
Jose Manuel Garcia-Manteiga et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Compromising the Unfolded Protein Response Induces Autophagy-Mediated Cell Death in Multiple Myeloma Cells
Anne-Sophie Michallet et al.
PLOS ONE (2011)
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Peter Walter et al.
SCIENCE (2011)
Ubiquitylation in ERAD: Reversing to Go Forward?
Yien Che Tsai et al.
PLOS BIOLOGY (2011)
The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress
Holger W. Auner et al.
BLOOD (2010)
The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation
Jiangbin Ye et al.
EMBO JOURNAL (2010)
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Maria-Victoria Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Biogenesis of secretory organelles during B cell differentiation
Semra J. Kirk et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells
Senthil K. Radhakrishnan et al.
MOLECULAR CELL (2010)
Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-Dependent Feedback Loop
Janos Steffen et al.
MOLECULAR CELL (2010)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
GCN2 Protein Kinase Is Required to Activate Amino Acid Deprivation Responses in Mice Treated with the Anti-cancer Agent L-Asparaginase
Piyawan Bunpo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Effect of autophagy on multiple myeloma cell viability
Bao Hoang et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat
Viviana I. Perez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
Qiuyan Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1
Dong Hoon Shin et al.
BLOOD (2008)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
One step at a time: endoplasmic reticulum-associated degradation
Shruthi S. Vembar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cholesterol levels in patients with multiple myeloma
Irfan Yavasoglu et al.
ANNALS OF HEMATOLOGY (2008)
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
D. A. Fennell et al.
ONCOGENE (2008)
The endoplasmic reticulum and the unfolded protein response
Jyoti D. Malhotra et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Narrative review: Protein degradation and human diseases: The ubiquitin connection
Eyal Reinstein et al.
ANNALS OF INTERNAL MEDICINE (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Progressively impaired proteasomal capacity during terminal plasma cell differentiation
S Cenci et al.
EMBO JOURNAL (2006)
Protein synthesis upon acute nutrient restriction relies on proteasome function
RM Vabulas et al.
SCIENCE (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells
P Cafforio et al.
CARCINOGENESIS (2005)
Phosphorylation of the α-subunit of the eukaryotic initiation factor-2 (eIF2α) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition
HY Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Principles of protein folding, misfolding and aggregation
CM Dobson
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation
AL Shaffer et al.
IMMUNITY (2004)
Protein degradation and protection against misfolded or damaged proteins
AL Goldberg
NATURE (2003)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
AH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
T Hideshima et al.
BLOOD (2003)
Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion
E van Anken et al.
IMMUNITY (2003)
The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides
AL Goldberg et al.
MOLECULAR IMMUNOLOGY (2002)
The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells
NWCJ van de Donk et al.
LEUKEMIA (2002)
The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction
MH Glickman et al.
PHYSIOLOGICAL REVIEWS (2002)
Regulation of starvation- and virus-induced autophagy by the eIF2α kinase signaling pathway
Z Tallóczy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Plasma cell differentiation requires the transcription factor XBP-1
AM Reimold et al.
NATURE (2001)
Share Paper
